Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's verapamil HCl
extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules
following evening administration of a single, oral 300 mg (1 x 300 mg) dose under fasting
conditions.